Department of Medical Oncology, Institut Català d'Oncologia (ICO), Institut d'Investigacions Biomèdiques de Bellvitge (IDIBELL), Duran i Reynals University Hospital, Barcelona, Spain.
Department of Medical Oncology, Marina Baixa de Villajoyosa Hospital, Alicante, Spain.
Clin Transl Oncol. 2023 Nov;25(11):3139-3151. doi: 10.1007/s12094-023-03286-3. Epub 2023 Aug 11.
Lung cancer (LC) is associated with ageing, with the average age of affected individuals being approximately 70 years. However, despite a higher incidence and prevalence among older people, the older adult population is underrepresented in clinical trials. For LC with Epidermal Growth Factor Receptor (EGFR) mutations, there is no clear association of this mutation with age. Geriatric assessments (GAs) and a multidisciplinary approach are essential for defining the optimal treatment. In this consensus, a group of experts selected from the Oncogeriatrics Section of the Spanish Society of Medical Oncology (Sección de Oncogeriatría de la Sociedad Española de Oncología Médica-SEOM), the Spanish Lung Cancer Group (Grupo Español de Cáncer de Pulmón-GECP) and the Association for Research on Lung Cancer in Women (Asociación para la Investigación del Cáncer de Pulmón en Mujeres-ICAPEM) evaluate the scientific evidence currently available and propose a series of recommendations to optimize the management of older adult patients with advanced LC with EGFR mutations.
肺癌（LC）与衰老有关，受影响个体的平均年龄约为 70 岁。然而，尽管老年人的发病率和患病率较高，但临床试验中老年人的代表性不足。对于具有表皮生长因子受体（EGFR）突变的 LC，这种突变与年龄没有明确的关联。老年评估（GA）和多学科方法对于确定最佳治疗方法至关重要。在本次共识中，来自西班牙肿瘤内科学会肿瘤老年病学分会（Sección de Oncogeriatría de la Sociedad Española de Oncología Médica-SEOM）、西班牙肺癌研究组（Grupo Español de Cáncer de Pulmón-GECP）和妇女肺癌研究协会（ Asociación para la Investigación del Cáncer de Pulmón en Mujeres-ICAPEM）的一组专家选择评估了目前可用的科学证据，并提出了一系列建议，以优化具有 EGFR 突变的晚期 LC 老年患者的管理。
